FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis

ABSTRACT: FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 has been identified as a potentially targetable oncogenic driver, notably in hepatocellular carcinoma (HCC). Nevertheless, FGF19 remained an attractive candidate for treatment of metabolic disease, prompting the development of analogs uncoupling its metabolic and tumor-promoting activities. Using pre-clinical mice models of somatic mutation driven HCC, we assessed the oncogenicity of FGF19 in combination with frequent HCC tumorigenic alterations: p53 inactivation, CTNNB1 mutation, CCND1 or MYC overexpression. Our data revealed a strong oncogenic cooperation between FGF19 and MYC. Most important

SUBMITTER: Dr. José Ursic-Bedoya 

PROVIDER: S-SCDT-10_1038-S44321-023-00021-X | biostudies-other |

REPOSITORIES: biostudies-other